Table 2.
Univariate analysis.
| Univariate analysis | 3 y GRFS | 3 y NRM | 3 y REL | 3 y OS | 3 y LFS |
|---|---|---|---|---|---|
| p | p | p | p | p | |
| SCT year | 0.4 | 0.85 | 0.15 | 0.6 | 0.3 |
| SCTyear ≤2014 | 42% | 20% | 16% | 64% | 58% |
| SCTyear > 2014 | 36% | 21% | 10% | 65% | 69% |
| ATLG vs PTCY | 0.22 | 0.86 | 0.4 | 0.9 | 0.54 |
| ATLG | 43% | 20% | 19% | 65% | 60% |
| PTCY | 34% | 21% | 12% | 64% | 67% |
| Match vs Mismatch | 0.9 | 0.55 | 0.64 | 0.39 | 0.4 |
| Match | 38% | 19% | 13% | 68% | 65% |
| Mismatch | 39% | 22% | 14% | 60% | 59% |
| Patient/Donor SEX | 0.9 | 0.31 | 0.46 | 0.38 | 0.36 |
| M/M | 39% | 19% | 19% | 63% | 60% |
| M/F | 35% | 31% | 5% | 64% | 58% |
| F/F | 35% | 25% | 17% | 58% | 58% |
| F/M | 43% | 12% | 6% | 81% | 74% |
| Patient/Donor CMV | 0.3 | 0.9 | 0.05 | 0.021 | 0.08 |
| neg/neg | 44% | 20% | 5% | 77% | 71% |
| neg/pos | 49% | 21% | 0% | 79% | 72% |
| pos/pos | 36% | 18% | 17% | 64% | 63% |
| pos/neg | 25% | 24% | 30% | 36% | 36% |
| ABO incompatibility | 0.47 | 0.47 | 0.18 | 0.69 | 0.67 |
| Compatible | 39% | 24% | 9% | 67% | 65% |
| Minor incomp. | 41% | 20% | 20% | 62% | 60% |
| Major incomp. | 46% | 14% | 11% | 70% | 67% |
| bidirectional incomp. | 20% | 13% | 27% | 53% | 53% |
| Patient age | 0.032 | 0.03 | 0.99 | 0.021 | 0.041 |
| ≤36 | 49% | 13% | 13% | 74% | 72% |
| >36 | 28% | 28% | 15% | 54% | 53% |
| Donor age | 0.33 | 0.87 | 0.09 | 0.28 | 0.29 |
| ≤37 | 37% | 19% | 19% | 64% | 61% |
| >37 | 40% | 22% | 8% | 66% | 65% |
| Stemcell source | 0.9 | 0.5 | 0.03 | 0.03 | 0.018 |
| BM | 40% | 25% | 25% | 50% | 47% |
| PBSC | 38% | 19% | 10% | 70% | 68% |
| CD34 infused cells | 0.88 | 0.14 | 0.45 | 0.05 | 0.049 |
| ≤6.7 | 38% | 26% | 15% | 56% | 53% |
| >6.7 | 39% | 14% | 12% | 75% | 72% |
| B-ALL vs T-ALL | 0.97 | 0.59 | 0.69 | 0.6 | 0.81 |
| B-ALL | 38% | 21% | 13% | 63% | 62% |
| T-ALL | 41% | 17% | 15% | 70% | 65% |
| BCR-ABL | 0.54 | 0.89 | 0.49 | 0.89 | 0.7 |
| Neg | 31% | 24% | 12% | 60% | 59% |
| Pos | 37% | 22% | 13% | 64% | 60% |
| MRD | 0.8 | 0.33 | 0.77 | 0.37 | 0.4 |
| Neg | 39% | 20% | 9% | 69% | 69% |
| Pos | 36% | 14% | 11% | 74% | 70% |
| Conditioning | 0.43 | 0.65 | 0.17 | 0.5 | 0.24 |
| TBICyVP16 | 44% | 23% | 17% | 62% | 54% |
| TBICy | 41% | 14% | 9% | 73% | 73% |
| TBIFlu | 34% | 21% | 12% | 64% | 60% |
| TBI dose | 0.32 | 0.61 | 0.02 | 0.22 | 0.23 |
| <12 Gy | 28% | 18% | 31% | 50% | 50% |
| 12 Gy | 40% | 21% | 10% | 68% | 65% |
Bold values indicate statistical significance p < 0.05.
3 y 3 years, OS overall survival, LFS leukemia-free survival, GRFS GvHD and relapse-free survival, CIR cumulative incidence of relapse, NRM non-relapse mortality, ALL acute lymphoblastic leukemia, ATLG anti-t-lymphocyte globulin, PTCy post- transplant cyclophosphamide, SCT stem cell transplantation, MRD minimal residual disease, CMV cytomegalo virus, BM bone marrow, PBSC peripheral blood stem cell, Cy cyclophosphamide, VP16 etoposide, Flu fludarabine, TBI total body irradiation.